FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?

Slides:



Advertisements
Similar presentations
JCAHO EXPECTATIONS FOR PRIMARY STROKE CENTER
Advertisements

Can we safely discharge TIA patients? Louis Muller EM Registrar January 2010.
Preventing Strokes One at a Time Acute Interventions and Management 2009.
Michael A. Ross, MD 1 Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies.
Michael Ross, MD, FACEP The Management of ED TIA Patients: Michael A. Ross MD FACEP Associate Professor Emergency Medicine Department of Emergency Medicine.
Management of Stroke and Transient Ischaemic Attack Sam Thomson.
Latha G. Stead, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Hyperacute Stroke Management Canadian Best Practice Recommendations for.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Stroke Mark Sudlow Consultant and Senior Lecturer
Michael A. Ross MD FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
ED TIA Patient Case Presentation Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Canadian Cardiovascular Society Antiplatelet Guidelines
Andrew W. Asimos, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Edward P. Sloan, MD, MPH FACEP ED Transient Ischemic Attack Patient Management: What Role for Outpatient Evaluation and Disposition?
J. Stephen Huff, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Management of E.D. Patients who Present with a Transient Ischemic Attack or.
The Management of ED TIA Patients:
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Brian J. O’Neil MD, FACEP The Management of TIA Patients: The Science and the Practice.
An Emergency Department Diagnostic Protocol For Patients With Transient Ischemic Attack: A Randomized Controlled Trial Michael A. Ross MD Scott Compton.
Preventing Strokes One at a Time Evaluating the Event 2009.
Michael Ross, MD, FACEP The Management of ED TIA Patients: Can We Send Them Home, and What Work-up Must Be Done First?
“Six Publications That Influence Neurological Emergency Patient Resuscitation in 2010”
Edward P. Sloan, MD, MPH, FACEP EMRA /FERNE Case Conference: The ED Management of TIA, AIS and ICH Patients.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Transient Ischemic Attack (TIA): The Calm Before the Storm
Andrew Asimos, MD, FACEP ED Transient Ischemic Attack Patient Management: Can At-risk Ischemic Stroke Patients Be Identified?
Hind Alnajashi. C AROTID ARTERY ANATOMY Common carotid artery Aortic arch Internal carotid MCA ACA Ophthalmic artery. Cervical segment Petrous segment.
Atrial Fibrillation Warfarin and its newer alternatives
Consultant Neurologist,
Secondary prevention after a TIA or ischemic stroke.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
‘STROKE’ September 2010 Dr. Amer Jafar.
Andrew W. Asimos, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Benefits of Urgent Evaluation and Treatment for TIA and Minor Stroke Summary and Comment by Kristi L. Koenig, MD, FACEP Published in Journal Watch Emergency.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
Clinical Correlations The NYU Internal Medicine Blog A Daily Dose of Medicine
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Medical Prevention of Stroke November 17, 2000 Ash Singhal University of Toronto.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Adult Medical-Surgical Nursing Neurology Module: Cerebrovascular Disease I (TIA)
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD.
Update on TIA Kath Pasco October  Primary prevention has been effective in fall in incidence of first stroke  Major improvements still required.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
DR AMER JAFAR ‘STROKE’ October Ethnicity and recurrence of stroke Population-based study Compared poststroke recurrence and survival in Mexican.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Rikki Weems, PGY III August 20, 2015
Cardioembolic Stroke: Diagnosis and Management
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Simon Howard Medical Management of Acute Stroke. Fast Recognition of Stroke With sudden onset neurological symptoms: 'FAST' should be used to screen for.
R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
Cryptogenic Stroke and AF
Alison Halliday Professor of Vascular Surgery University of Oxford
Risk Stratification of Chest Pain: Best Practices
Cerebrovascular Disorders
Quality of Referrals Guideline Congruence of referrals to TIAMS clinic
Setareh Omran, MD Vascular Neurology Fellow
European Heart Association Journal 2007 April
TIA/Stroke (1) C.L.I.P.S. Why do we care?
Stroke: The Brain Attack
INTRODUCTION TO THE STROKE PROGRAM. INTRODUCTION TO THE STROKE PROGRAM.
Presentation transcript:

FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?

FERNE/EMRA Michael A. Ross MD FACEP Associate Professor of Emergency Medicine Department of Emergency Medicine William Beaumont Hospital Wayne State University School of Medicine

FERNE/EMRA An Emergency Department Diagnostic Protocol For Patients With Transient Ischemic Attack: A Randomized Controlled Trial To determine if emergency department TIA patients managed using an accelerated diagnostic protocol (ADP) in an observation unit (EDOU) will experience: shorter length of stays lower costs comparable clinical outcomes... relative to traditional inpatient admission.

FERNE/EMRA ADP Exclusion criteria Clinical: Clinical: Stroke / creshendo TIAs / Positive HCT / Large prior CVA Stroke / creshendo TIAs / Positive HCT / Large prior CVA Known clot source: Known clot source: Atrial fib, carotid stenosis >50%, major valve ds, PFO Atrial fib, carotid stenosis >50%, major valve ds, PFO Non-focal symptoms: Non-focal symptoms: HT encephalopathy, severe dementia HT encephalopathy, severe dementia Social issues: Social issues: Discharge unlikely, IV drug use, to survive beyond study follow up period Discharge unlikely, IV drug use, to survive beyond study follow up period

FERNE/EMRA Four ADP Interventions : Four ADP Interventions : Serial neuro exams Serial neuro exams Unit staff, physician, and a neurology consult Unit staff, physician, and a neurology consult Cardiac monitoring Cardiac monitoring Carotid dopplers Carotid dopplers 2-D echo 2-D echo ADP discharge criteria ADP discharge criteria No recurrent deficits, negative workup No recurrent deficits, negative workup Appropriate antiplatelet therapy and follow-up Appropriate antiplatelet therapy and follow-up EDOU TIA DIAGNOSTIC PROTOCOL

FERNE/EMRA Results: Performance of clinical testing

FERNE/EMRA Results: Length of Stay Median Inpatient = 61.2 hr ADP = 25.6 hr Difference= 29.8 hr (Hodges-Lehmann) (p<0.001) ADP sub-groups: ADP - home= 24.2 hr ADP - admit= hr

FERNE/EMRA Results: 90-Day Clinical Outcomes

FERNE/EMRA Results: 90 - day Costs Median Inpatient = $1548 ADP = $890 Difference= $540 (Hodges-Lehmann) (p<0.001) ADP sub-groups: ADP - home= $844 ADP - admit= $2,737

FERNE/EMRA Five critical issues: 1. Appropriate history and physical 2. ECG, monitor, HCT 3. Carotid dopplers - why, when, how? 4. Further clinical testing – echo, etc 5. Therapy – starting with aspirin

FERNE/EMRA 1. History and physical - definition of TIA Re-definition of TIA Re-definition of TIA …a brief episode of neurologic dysfunction …a brief episode of neurologic dysfunction caused by focal brain or retinal ischemia, caused by focal brain or retinal ischemia, with clinical symptoms typically lasting less than 1hr, with clinical symptoms typically lasting less than 1hr, and without evidence of acute infarction”. and without evidence of acute infarction”.

FERNE/EMRA Utility of the H/P? TIA risk stratification TIA risk stratification Johnston criteria Johnston criteria Rothwell criteria - “ABCD” Rothwell criteria - “ABCD” Combination of the above => stay tuned Combination of the above => stay tuned

FERNE/EMRA 2. HCT, ECG ECG – ATRIAL FIBRILLATION!!! ECG – ATRIAL FIBRILLATION!!! Stroke risk – cardio-embolic risk Stroke risk – cardio-embolic risk 4.6% at 1 month 4.6% at 1 month 11.9% at 3 months 11.9% at 3 months 61% reduction in annual risk of stroke (both ischemic or hemorrhagic) with coumadin 61% reduction in annual risk of stroke (both ischemic or hemorrhagic) with coumadin

FERNE/EMRA 2. HCT, ECG HCT - tumor, SDH, NPH, etc HCT - tumor, SDH, NPH, etc Minor stroke and TIA associated with a 10% incidence of stroke on MRI. Minor stroke and TIA associated with a 10% incidence of stroke on MRI.

FERNE/EMRA 3. Carotid Dopplers Stroke risk depends on where the disease is: 7day90day CE = Cardio-Embolic:2.5%12% LAA = Large arteries 4.0%19% Und = Undetermined 2.3%9% SVS = Small Vessels 0%3%

FERNE/EMRA 3. Carotid dopplers The BIG question - WHEN??? Carotid surgery if >70% stenosis lesions is “time sensitive”. Carotid surgery if >70% stenosis lesions is “time sensitive”. Stroke risk reduction if done within: Stroke risk reduction if done within: 0-2 weeks 0-2 weeks 75% stenosis = 30.2% 75% stenosis = 30.2% 2-4 weeks 2-4 weeks 75% stenosis = 17.6% 75% stenosis = 17.6% 4-12 weeks 4-12 weeks 75% stenosis = 11.4% 75% stenosis = 11.4% +12 weeks +12 weeks 75% stenosis = 8.9% 75% stenosis = 8.9% Similar for 50-70% lesions Similar for 50-70% lesions

FERNE/EMRA 4. Further Clinical testing? Serial neurological exams? Serial neurological exams? 10.5% stroke within 3 months 10.5% stroke within 3 months Half within 2 days Half within 2 days Most within 1 day Most within 1 day Monitoring for AF? Monitoring for AF? 2-D echo? 2-D echo?

FERNE/EMRA 5. Medical management Antiplatelet Therapy for non-cardioembolic cases: Antiplatelet Therapy for non-cardioembolic cases: Aspirin mg/day Aspirin mg/day Clopidogrel or ticlopidine Clopidogrel or ticlopidine Aspirin plus dipyridamole Aspirin plus dipyridamole Latter two if ASA intolerant or if TIA while on ASA Latter two if ASA intolerant or if TIA while on ASA Framingham risk factor management Framingham risk factor management Routine anticoagulation not recommended Routine anticoagulation not recommended